Philadelphia, United States
Longevity Biotech is a biotechnology company founded in 2010 and headquartered in the United States. The company is focused on developing new therapeutic drug candidates with the potential to have a direct clinical impact on patients' lives. Their approach is centered around their proprietary Hybridtide peptide scaffold technology, which is designed for long-acting oral administration.
Their most recent investment, a $316.38K grant, was secured on 09 November 2017 from the National Multiple Sclerosis Society (NMSS). This funding reflects confidence from a reputable organization in Longevity Biotech's approach and potential impact in the health and wellness and pharmaceutical sectors.
